Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.74 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.74 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.74 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.74 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.74 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.74 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.74 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.74 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.74 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | FAAH | O00519 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL4023094 | 0.91 | GABRA1 (0.81) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL4022545 | 0.87 | GABRA1 (0.74) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL36245 | 0.86 | GABRA1 (1.00) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL2414429 | 0.86 | GABRA1 (1.00) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL2678655 | 0.86 | GABRA1 (0.65) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL29792946 | 0.85 | GABRA1 (0.71) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL1033835 | 0.84 | GABRA1 (0.94) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL10968613 | 0.84 | GABRA1 (0.94) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL10968616 | 0.84 | GABRA1 (0.94) | GABRA1LMNAGABRB1GABRB2GABRG2 | |
| Propofol SCHEMBL5036811 | 0.84 | GABRA1 (0.94) | GABRA1LMNAGABRB1GABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103781472-B | Synthesis and use of propofol glycoside derivatives | 纽泰克制药有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9023813-B2 | Synthesis and use of glycoside derivatives of propofol | NuTek Pharma Ltd. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-103781472-A | Synthesis and use of propofol glycoside derivatives | NUTEK PHARMA LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103702670-A | Synthesis and use of glycoside pro-drug analogs | NUTEK PHARMA LTD | 2014-04-02 | — | — | CN | disclosed |
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-11-22 | — | — | US | disclosed |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | NuTek Pharma Ltd. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142147-A2 | SYNTHESIS AND USE OF GLYCOSIDE DERIVATIVES OF PROPOFOL | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142141-A1 | SYNTHESIS AND USE OF GLYCOSIDE PRO-DRUG ANALOGS | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | GCG, CYP3A5, UGT1A6 | GABRA1 2014/4885GABRB1 2448/4885GABRB2 2594/4885 |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | CYP3A5, CYP3A4, UGT1A4 | GABRA1 193/4885GABRB1 362/4885GABRB2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.